Skip to main content

Advertisement

SpringerLink
Log in

The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

In the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancer patients and also prognostic factors related with recurrence-free survival (RFS) in recurrent patients.

Patients/methods

We evaluated retrospectively 1980 breast cancer patients. Relapsed was defined as early if it was occured first 5 year of follow-up (Group 1) and late if it was occured after 5 years (Group 2). The clinicopathological factors were compared in respect of time of recurrence. The prognostic factors were evaluated using univariate and multivariate analyses.

Results

Recurrence wase detected in 141 patient during follow-up. Tumors recurred after 5 years more likely to have lower stage (p = 0.05), tumors without lymphovascular invasion (LVI) (p < 0.001) and perineural invasion (PNI) (p = 0.01), and also HER2 negative (p < 0.001). The median RFS time and 5 years RFS rates were 42.9 months and 31.9 %, respectively. LVI (p = 0.01), PNI (p = 0.03), HER2 (p = 0.003), progesterone receptor (PR) (p = 0.04), the presence of neoadjuvant chemotherapy (p = 0.003), adjuvant hormonotherapy (p = 0.05) were found to be related with RFS. Axillary lymph node metastasis (p = 0.05) and the presence of PNI (p = 0.009) were poor prognostic factors for early recurrent group. PR-positive tumors (p = 0.001) and luminal subtypes (p = 0.03) had instances of late recurrences significantly.

Conclusions

Clinicopathological factors predicting the recurrence time in breast cancer were important to modify adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7.

    Article  CAS  PubMed  Google Scholar 

  2. Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, et al. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer. 2008;112:1437–44.

    Article  CAS  PubMed  Google Scholar 

  3. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1995;13:314–22.

    CAS  PubMed  Google Scholar 

  4. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996;41:177–85.

    Article  CAS  PubMed  Google Scholar 

  5. Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer. 1988;62:2226–33.

    Article  CAS  PubMed  Google Scholar 

  6. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.

    CAS  PubMed  Google Scholar 

  7. Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast Cancer (Auckl). 2013;7:23–34.

    PubMed Central  PubMed  Google Scholar 

  8. Song WJ, Kim KI, Park SH, Kwon MS, Lee TH, Park HK, et al. The Risk Factors Influencing between the Early and Late Recurrence in Systemic Recurrent Breast Cancer. J Breast Cancer. 2012;15:218–23.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907–22.

    PubMed Central  PubMed  Google Scholar 

  10. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. N Engl J Med. 1995;333:1444–55.

    Article  Google Scholar 

  11. Arriagada R, Lê MG, Guinebretière JM, Dunant A, Rochard F, Tursz T. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol. 2003;14:1617–22.

    Article  CAS  PubMed  Google Scholar 

  12. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol. 2007;18:45–51.

    Article  CAS  PubMed  Google Scholar 

  13. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:1179–83.

    Article  PubMed  Google Scholar 

  14. Bosco JL, Lash TL, Prout MN, Buist DS, Geiger AM, Haque R, et al. BOW Investigators. Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009;18:2979–83.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Takeuchi H, Tsuji K, Ueo H. Prediction of early and late recurrence in patients with breast carcinoma. Breast Cancer. 2005;12:161–5.

    Article  PubMed  Google Scholar 

  16. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Béraud T, Gómez F. The predictive value of estrogen and progesterone receptors’ concentrations on the clinical behaviour of breast cancer in women. Clinical correlation on 547 patients. Cancer. 1986;57:1171–80.

    Article  CAS  PubMed  Google Scholar 

  17. Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, et al. Locoregional recurrence in patients with HER2 positive breast cancer. Breast. 2013;22:856–62.

    Article  PubMed  Google Scholar 

  18. Ahn SG, Lee HM, Cho SH, Bae SJ, Lee SA, Hwang SH, et al. The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence. PLoS One. 2013;8(5):e63510.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8.

    Article  PubMed  Google Scholar 

  20. Jagsi R, Raad RA, Goldberg S, Sullivan T, Michaelson J, Powell SN, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;62:1035–9.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declared that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, HaydarpasaNumuneEducation and Research Hospital, Selimiye Mah, Şair Nesimi sok, Kardeşler Apt., No: 1, Daire: 4, Uskudar, 34668, Istanbul, Turkey

    B. B. Oven Ustaalioglu & B. Erkol

  2. Department of Medical Oncology, Dr. LutfiKirdarKartal Education and Research Hospital, Istanbul, Turkey

    O. Balvan, A. Develi & M. Aliustaoglu

  3. Department of Medical Oncology, Medipol University, Istanbul, Turkey

    A. Bilici

  4. Department of Pathology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey

    F. A. Vardar

Authors
  1. B. B. Oven Ustaalioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Balvan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Bilici
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Develi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Aliustaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. A. Vardar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Erkol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. B. Oven Ustaalioglu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oven Ustaalioglu, B.B., Balvan, O., Bilici, A. et al. The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival. Clin Transl Oncol 17, 895–902 (2015). https://doi.org/10.1007/s12094-015-1323-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1323-x

Keywords

Search

Navigation